Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05.
Published March 8, 2023 · Recall initiated: February 17, 2023
Summary
FDA records drug Class III recall D-0354-2023, published March 8, 2023 and initiated February 17, 2023. Recalling firm: Sciegen Pharmaceuticals Inc; Status: Terminated; Reported quantity: 4,392 bottles; Lot: Lot # G177092, Exp. 11/24. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.
What to do
Voluntary: Firm initiated · Letter
Get an email if GABAPENTIN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- GABAPENTIN
- Manufacturer
- Sciegen Pharmaceuticals Inc
- Distributor
- Nationwide in the USA and Puerto Rico
- UPC
- 0350228180108
- Lot
- Lot # G177092, Exp. 11/24
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAGabapentin Capsules, USP, 100 mg, 100 Capsules (10 x 10 blister packs), Rx only, Packaged and Distributed by:October 29, 2025
- FDAGabapentin Capsules, USP, 100 mg, 10 Capsules (10 x 1 blister pack), Rx only, Packaged and Distributed by:October 29, 2025
- FDAGabapentin Capsules, USP, 100 mg, 100 capsules (10x10), blister pack cartons, Rx only, Packaged andJuly 9, 2025
- FDAGabapentin Capsules, USP, 100 mg, 10 capsules (10x1) per bag, Rx only, Packaged and Distributed by: MAJORJuly 9, 2025
- FDALevothyroxine Sodium Tablets, USP 112 mcg, 90 tablets per bottle, Rx Only, Manufactured by Lloyd Inc.,March 8, 2023
- FDADiltiazem HCl in 0.7% Sodium Chloride Injection, 125 mg/125 mL (1 mg/mL), 125 mL Single-Dose Container bottle,March 8, 2023
Questions about this recall
Was Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05. recalled?
Yes. FDA published recall D-0354-2023 on March 8, 2023. Reported hazard: Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: GABAPENTIN. UPC: 0350228180108.